Evidence map›Paper›PMID 32876803›Full record

ReviewJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2020

Opioid and neuroHIV Comorbidity - Current and Future Perspectives.

Sylvia Fitting, MaryPeace McRae, Kurt F Hauser

Open access · hybridAbstract readReview
In one paragraph

Review in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Epigenetic mechanisms of HIV and opioid-induced neuropathology: Potential therapies and interventions.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Sylvia FittingDepartment of Psychology and Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599-3270, USA.
MaryPeace McRaeDepartment of Pharmacotherapy and Outcomes Science, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, 23298, USA.
Kurt F HauserDepartment of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, 1217 East Marshall Street, Richmond, VA, 23298-0613, USA. kurt.hauser@vcuhealth.org.ORCID 0000-0001-7886-0332
Virginia Commonwealth University · USUniversity of North Carolina at Chapel Hill · US

Funding

MOR and CCR5 interactive signaling mediates opiate and HIV-driven synaptodendritic injuryR01DA034231 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI HAUSER, KURT F, KNAPP, PAMELA E · 2013 to 2023
$5.4M
Mechanisms of Opiate Drug-HIV-Induced NeurodegenerationR01DA018633 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI HAUSER, KURT F · 2005 to 2021
$4.4M
HIV opiate interactions in white matter pathologyR01DA044939 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI HAUSER, KURT F, KNAPP, PAMELA E · 2017 to 2021
$2.7M
Bivalent Ligands as Chemical Probes to Study Opioid Abuse-enhanced HIV InfectionR01DA044855 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI HAUSER, KURT F, ZHANG, YAN · 2017 to 2021
$2.7M
Selective vulnerability of discrete neural circuits in the striatum to HIV-opiate comorbidityR01DA045588 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI HAUSER, KURT F · 2018 to 2022
$2.0M
Endocannabinoid-mediated neuroprotection in models of neuroAIDS in vivoR01DA045596 · NIDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI FITTING, SYLVIA · 2018 to 2022
$1.9M
The interactive effects of HIV and opiates in therapeutic drug penetration into the brainR21DA045630 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI MCRAE, MARY PEACE · 2018 to 2019
$426k
NIDA NIH HHS R01 DA018633NIDA NIH HHS R01 DA034231NIDA NIH HHS R01 DA044855NIDA NIH HHS R01 DA044939NIDA NIH HHS R01 DA045588NIDA NIH HHS R01 DA045596NIDA NIH HHS R21 DA045630
6 · The paper itself

Abstract

With the current national opioid crisis, it is critical to examine the mechanisms underlying pathophysiologic interactions between human immunodeficiency virus (HIV) and opioids in the central nervous system (CNS). Recent advances in experimental models, methodology, and our understanding of disease processes at the molecular and cellular levels reveal opioid-HIV interactions with increasing clarity. However, despite the substantial new insight, the unique impact of opioids on the severity, progression, and prognosis of neuroHIV and HIV-associated neurocognitive disorders (HAND) are not fully understood. In this review, we explore, in detail, what is currently known about mechanisms underlying opioid interactions with HIV, with emphasis on individual HIV-1-expressed gene products at the molecular, cellular and systems levels. Furthermore, we review preclinical and clinical studies with a focus on key considerations when addressing questions of whether opioid-HIV interactive pathogenesis results in unique structural or functional deficits not seen with either disease alone. These considerations include, understanding the combined consequences of HIV-1 genetic variants, host variants, and μ-opioid receptor (MOR) and HIV chemokine co-receptor interactions on the comorbidity. Lastly, we present topics that need to be considered in the future to better understand the unique contributions of opioids to the pathophysiology of neuroHIV. Graphical Abstract Blood-brain barrier and the neurovascular unit. With HIV and opiate co-exposure (represented below the dotted line), there is breakdown of tight junction proteins and increased leakage of paracellular compounds into the brain. Despite this, opiate exposure selectively increases the expression of some efflux transporters, thereby restricting brain penetration of specific drugs.

Indexed as

COVID-19Opioid EpidemicAIDS Dementia ComplexHIV-1HIV InfectionsHumansOpioid-Related DisordersAntiretroviral therapyAstrocyteBlood-brain barrierBuprenorphineC-C motif chemokine receptor 5 (CCR5)COVID-19Cytochrome P450 3A4 (CYP 3A4)Endogenous opioid system of peptides and receptorsFunctional selectivity/biased agonismHIV-associated neurocognitive disordersMaladaptive neuroplasticityMethadoneMicroglianeuroHIVOligodendrogliaP-glycoproteinPro-brain-derived neurotrophic factor (pro-BDNF)Synaptodendritic degenerationμ-Opioid receptor (OPRM1)

Identifiers

PMID32876803
PMCPMC7463108
OpenAlexW3081659762

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.